Exploring the Druggablity of Novel Small Molecules that Targets TFF3, Hyaluronidase, and Jak-Stat3 Pathway in in Vivo Cancer and Functional Remyelination Models
Proceedings of International Conference on Drug Discovery (ICDD) 2020
Posted: 18 Feb 2020
Date Written: February 17, 2020
Increased expression of TFF3 has been reported in colorectal carcinoma. Herein, the functional roles of TFF3 and the pharmacological inhibition of TFF3 by a novel specific small molecule TFF3 inhibitor, AMPC in CMS4 CRC was explored. Aberrant activation of STAT3 has been observed in a wide range of human malignancies. Hence, we performed high-throughput virtual screening in search of STAT3 signaling inhibitors using a cheminformatics platform and identified CIMO as the inhibitor of the STAT3 signaling pathway. We also tested the possibility that hyaluronidase activity is directly linked to the inhibition of OPC maturation by developing a novel modified flavonoid that functions as a hyaluronidase inhibitor.
Keywords: Drug discovery, hyaluronidase, TFF3, BAD, STAT3
Suggested Citation: Suggested Citation